Evaluation of serum autoantibody levels in the diagnosis of ovarian endometrioma

Objective: We analyzed autoantibodies against tumor‐associated antigens (TAAs) in the serum of patients with endometrioma and healthy controls to determine whether autoantibodies can be accurate biomarkers for the diagnosis of ovarian endometrioma. Methods: Serum samples were obtained from 56 patients with endometriosis and 66 healthy women who served as normal controls. The titers of antibodies against a panel of eight TAAs were analyzed using enzyme‐linked immunosorbent assay. Results: We found that the serum IGFII mRNA‐binding protein 1 (IMP1) autoantibody and cyclin B1 autoantibody could discriminate between healthy controls and endometriosis patients (AUC–ROC 0.777; 95% confidence interval [CI] 0.694–0.860, P